Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.

Annals of clinical and laboratory science - 1 Jan 2014

Ha Jung-Sook, Jeon Dong-Seok, Kim Jae-Ryong, Ryoo Nam-Hee, Suh Jang-Soo

Abstract excerpt

Loss-of-function mutations in the putative tumor suppressor gene, Ten-Eleven Ttranslocation 2(TET2), have been identified recently in myeloproliferative neoplasms (MPNs). The present study analyzed the TET2 gene in 99 MPNs patients. The overall TET2 mutational frequency was 12.1% (22.2% in polycythemia vera (PV), 9.7% in essential thrombocythemia (ET), 18.2% in primary myelofibrosis (PMF,) and 0% in unclassified...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Bone Marrow Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Codon, Nonsense

Share to Dioxygenases

Share to Frameshift Mutation

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 24795056

Genes

TET2
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.PMID 24795056Read ↗

TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.Semantic proximity Read ↗

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.Semantic proximity Read ↗

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.Semantic proximity Read ↗

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).Semantic proximity Read ↗

TET2 mutations in secondary acute myeloid leukemias: a French retrospective study.Semantic proximity Read ↗

Clinical Impact of Next-Generation Sequencing-Detected Mutations on Thrombotic Events in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.Semantic proximity Read ↗

Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.Semantic proximity Read ↗

A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.